Vol. 6 No. 1 (2026)
Reimbursement Reviews

Durvalumab (Imfinzi)

decorative image of the issue cover

Published January 8, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Durvalumab (Imfinzi), 50 mg/mL, concentrate for IV infusion
  • Indication: Imfinzi (durvalumab), as monotherapy, indicated for the treatment of adult patients with limited-stage small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy.